BRIEF—BioNTech 3rd-qtr 2021 financial results

German biotech BioNTech, which sprung into the limelight with the first launch of a COVID-19 vaccine in partnership with US pharma giant Pfizer, today reported financial results, sending its New York-listed shares up 12%.

Total revenues were estimated to be 6,087.3 million euros ($7.05 billion) for the three months ended September 30, 2021, compared to 67.5 million euros for the like 2020 period.  The increase was mainly due to rapid increases in the supply and sales of the COVID-19 vaccine, trade name Comirnaty, worldwide.

Under the collaboration agreements, territories have been allocated between BioNTech, Pfizer and Fosun Pharma based on marketing and distribution rights. During the three months BioNTech’s commercial revenues included an estimated amount of 4,341.5 million euros gross profit share and 17.0 million euros of sales milestones.

Net profit was 3,211.0 million euros for the 2021 third quarter, compared to a 210.0 million euros net loss for the like 2020 quarter.

Estimated BioNTech Comirnaty/COVID-19 vaccine revenues for the full 2021 financial year based on up to 2.5 billion doses is around 16 billion to 17 billion euros.